Ewch i’r prif gynnwys
Dr Alex Baldwin

Dr Alex Baldwin

Research Associate

Ysgol y Biowyddorau

Email:
baldwina4@cardiff.ac.uk
Telephone:
+44 (0)29 2251 1078
Location:
Y Prif Adeilad, Plas y Parc, Caerdydd, CF10 3AT

I am a synthetic/medicinal chemist currently working in the newly-established Medicines Discovery Institute to develop novel drugs to treat diseases of high unmet clinical need, with a particular emphasis on neuroscience and mental health. I have previously contributed to a number of drug discovery projects, providing medicinal chemistry support to translate exciting new discoveries in human disease into potential drug candidates, primarily in the neurodegeneration area.

I have expertise in medicinal chemistry and drug design, including target identification/validation, hit-to-lead and multi-parameter lead optimisation, and IP protection.

I have a BSc (with Honours) in Biological and Medicinal Chemistry from the University of Exeter and a PhD in Medicinal Chemistry from The University of Manchester, under the supervision of Dr. Sally Freeman.

During my PhD, I was the lead medicinal chemist responsible for hit-to-lead and lead optimisation of a novel class of boron-based inhibitors of the NLRP3 inflammasome, an exciting therapeutic target implicated in a wide range of non-communicable diseases such as gout, atherosclerosis, type 2 diabetes and Alzheimer's disease. A drug candidate from this drug discovery program has now entered pre-clinical evaluation in animal models of Alzheimer's disease in collaboration with the Dementia Consortium. I have also contributed to the repurposing of fenamate NSAIDs for the treatment of Alzheimer's disease, which attracted considerable national media interest and has led to preparation for a Phase II clinical trial for dementia. Other drug discovery projects I worked on during my PhD includes the development of novel VRAC inhibitors for the treatment of Alzheimer's disease, synthesis and evaluation of improved antibacterial agents, and development of NQO2 inhibitors for the treatment of cancer and malaria.

I am a Member of the Royal Society of Chemistry (MRSC) and a member of the Biochemical Society.

2018

2017

2016

2015